A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer Meeting Abstract
| Authors: | Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; Mileshkin, L. R.; Lee, Y. C.; Miller, R.; Yoo, S. Y.; Peterman, M. J.; Schmidt, T.; Knorr, D.; Lowy, I.; Uldrick, T. S.; Miller, E. |
| Abstract Title: | A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406270 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS5632 |
| Notes: | Meeting Abstract: TPS5632 -- Source: Wos |
